Cargando…
Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan
Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that de...
Autores principales: | Sato, Toshihiro, Kodama, Shinjiro, Kaneko, Keizo, Imai, Junta, Katagiri, Hideki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239866/ https://www.ncbi.nlm.nih.gov/pubmed/35468049 http://dx.doi.org/10.3201/eid2807.220127 |
Ejemplares similares
-
Simultaneous Copy Number Losses within Multiple Subtelomeric Regions in Early-Onset Type2 Diabetes Mellitus
por: Kodama, Shinjiro, et al.
Publicado: (2014) -
Insulin-like growth factor-1 levels are associated with high comorbidity of metabolic disorders in obese subjects; a Japanese single-center, retrospective-study
por: Kubo, Haremaru, et al.
Publicado: (2022) -
Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment
por: Hatayama, Satoko, et al.
Publicado: (2022) -
A case of fulminant type 1 diabetes and protein C deficiency complicated by deep vein thrombosis
por: Kohata, Masato, et al.
Publicado: (2023) -
Insulin allergy manifesting soon after COVID‐19 vaccination (BNT162b2)
por: Komamura, Hiroshi, et al.
Publicado: (2022)